Sanofi Genzyme, a division of sanofi-aventis Canada Inc.
Call for patient/clinician input open:
Call for patient/clinician input closed:
NOC Status at Filing:
Manufacturer Requested Reimbursement Criteria1:
As per Health Canada submitted indication, for the long-term treatment of patients with Pompe disease and as per current access of the other ERT available for the treatment of Pompe Disease, Alglucosidase alfa (Myozyme).
Avalglucosidase alfa is an enzyme replacement therapy (ERT) indicated for the long-term treatment of patients with Pompe disease (acid Î±-glucosidase deficiency).
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.